>
Uploading C:\Program Files\Stnexp\Queries\10551557-broad.str



chain nodes :
8 9 10 11 12 13 14 15 16 17 30
ring nodes :
1 2 3 4 5 6 18 19 20 21 22 23
chain bonds :
5-8 8-9 9-10 10-11 10-12 12-13 13-14 14-15 14-16 16-17 17-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 18-19 18-23 19-20 20-21 21-22 22-23
exact/norm bonds :
5-8 8-9 9-10 10-11 10-12 12-13 13-14 14-15 14-16 16-17 17-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 18-19 18-23 19-20 20-21 21-22 22-23
isolated ring systems :
containing 1 : 18 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 10:CLASS 11:CLASS
12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 30:Atom 31:Atom

L4 STRUCTURE UPLOADED

FILE 'REGISTRY' ENTERED AT 12:01:32 ON 22 MAY 2008
L1 3362851 S NC5/ES
L2 548380 S NC2OC2/ES
L3 57414 S L1 AND L2
L4 STRUCTURE UPLOADED

L6 14 S L4 SSS FULL SUB=L3

FILE 'CAPLUS' ENTERED AT 12:02:25 ON 22 MAY 2008
L7 5 S L6

L8 2 S US200!-551557/APPS
L9 2 S L8 AND L7

L11 3 S L7 NOT L8

=> d l9 tot bib abs

L9 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:857551 CAPLUS <<LOGINID::20080522>>
DN 141:350179
TI Preparation of azolidinedicarboxamides and related compounds as Factor Xa and Factor VIIa inhibitors
IN Tsaklakidis, Christos; Dorsch, Dieter; Mederski, Werner; Cezanne, Bertram;

Gleitz, Johannes
PA Merck Patent GmbH, Germany
SO PCT Int. Appl., 162 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 5

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2004087646 | A2 | 20041014 | WO 2004-EP2350 | 20040308 |
| WO 2004087646 | A3 | 20050106 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| DE 10315377 | A1 | 20041014 | DE 2003-10315377 | 20030403 |
| DE 10329295 | A1 | 20050203 | DE 2003-10329295 | 20030630 |
| AU 2004226278 | A1 | 20041014 | AU 2004-226278 | 20040308 |
| CA 2521069 | A1 | 20041014 | CA 2004-2521069 | 20040308 |
| BR 2004008420 | A | 20060321 | BR 2004-8420 | 20040308 |
| JP 2006522033 | T | 20060928 | JP 2006-504581 | 20040308 |
| EP 1720844 | A2 | 20061115 | EP 2004-718299 | 20040308 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LT, LV | | | | |
| IN 2005KN01684 | A | 20070727 | IN 2005-KN1684 | 20050823 |
| US 20060183739 | A1 | 20060817 | US 2005-551557 | 20051003 <-- |
| PRAI DE 2003-10315377 | A | 20030403 | | |
| DE 2003-10329295 | A | 20030630 | | |
| US 2003-483897P | P | 20030702 | | |
| WO 2004-EP2350 | W | 20040308 | | |

OS MARPAT 141:350179
GI



I

AB R1R2(TYX)EWCOGD [R1, R2 = H, O, halo, A, ethynyl, OR3, N(R3)2, NO2, cyano, N3, CO2R3, CON(R3)2, etc.; R3 = H, A, HC.tplbond.CCH2, MeC.tplbond.CCH2, CH2CH(OH)CH2OH, etc.; R4 = H, A; W = N, C, CR3; E = atoms to form a 3-7 membered (heterocyclic) ring optionally containing a double bond; D = mono- or dinuclear (substituted) (hetero)aryl; G = [C(R4)2]n, [C(R4)2]nNR3, [C(R4)2]nO, [C(R4)2]nS, etc.; n = 0-2; X = [C(R4)2]nCO[C(R4)2]n, [C(R4)2]n,NR3[C(R4)2]n, [C(R4)2]nNR3CO[C(R4)2]n, etc.; Y = alkylene, cycloalkylene, heterocyclylene, arenediyl; T = substituted mono- or dinuclear carbocyclyl, heterocyclyl; A = (fluoro-substituted) alkyl

optionally interrupted by O, S, CH:CH], were prepared Thus, title compound (I) [preparation from 4-(4-aminophenyl)morpholin-3-one, Boc-D-proline, and 4-chlorophenyl isocyanate given] bound to Factor Xa receptors with IC50 = 1.8 + 10-8 M.

L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:841766 CAPLUS <<LOGINID::20080522>>
DN 141:332202
TI Preparation of azolidinecarboxamides as antithrombotics and anticancer drugs.
IN Tsaklakidis, Christos; Dorsch, Dieter; Mederski, Werner; Cezanne, Bertram; Gleitz, Johannes
PA Merck Patent GmbH, Germany
SO Ger. Offen., 47 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | DE 10315377 | A1 | 20041014 | DE 2003-10315377 | 20030403 |
| | AU 2004226278 | A1 | 20041014 | AU 2004-226278 | 20040308 |
| | CA 2521069 | A1 | 20041014 | CA 2004-2521069 | 20040308 |
| | WO 2004087646 | A2 | 20041014 | WO 2004-EP2350 | 20040308 |
| | WO 2004087646 | A3 | 20050106 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | BR 2004008420 | A | 20060321 | BR 2004-8420 | 20040308 |
| | CN 1771237 | A | 20060510 | CN 2004-80009354 | 20040308 |
| | JP 2006522033 | T | 20060928 | JP 2006-504581 | 20040308 |
| | EP 1720844 | A2 | 20061115 | EP 2004-718299 | 20040308 |
| | R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LT, LV | | | | |
| | AU 2004226280 | A1 | 20041014 | AU 2004-226280 | 20040309 |
| | AU 2004226281 | A1 | 20041014 | AU 2004-226281 | 20040309 |
| | CA 2520893 | A1 | 20041014 | CA 2004-2520893 | 20040309 |
| | CA 2520894 | A1 | 20041014 | CA 2004-2520894 | 20040309 |
| | WO 2004087695 | A1 | 20041014 | WO 2004-EP2405 | 20040309 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | WO 2004087696 | A1 | 20041014 | WO 2004-EP2407 | 20040309 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, | | | | |

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

| | | | | | |
|---|---|---|---|---|---|
| EP | 1608645 | A1 | 20051228 | EP 2004-718641 | 20040309 |
| EP | 1608645 | B1 | 20070502 | | |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK | | | | |
| EP | 1608646 | A1 | 20051228 | EP 2004-718646 | 20040309 |
| EP | 1608646 | B1 | 20070711 | | |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK | | | | |
| BR | 2004008444 | A | 20060404 | BR 2004-8444 | 20040309 |
| BR | 2004008888 | A | 20060411 | BR 2004-8888 | 20040309 |
| CN | 1771248 | A | 20060510 | CN 2004-80009374 | 20040309 |
| CN | 1771249 | A | 20060510 | CN 2004-80009463 | 20040309 |
| JP | 2006522037 | T | 20060928 | JP 2006-504602 | 20040309 |
| JP | 2006522038 | T | 20060928 | JP 2006-504604 | 20040309 |
| AT | 361296 | T | 20070515 | AT 2004-718641 | 20040309 |
| AT | 366732 | T | 20070815 | AT 2004-718646 | 20040309 |
| ES | 2285444 | T3 | 20071116 | ES 2004-718641 | 20040309 |
| ES | 2287708 | T3 | 20071216 | ES 2004-718646 | 20040309 |
| IN | 2005KN01684 | A | 20070727 | IN 2005-KN1684 | 20050823 |
| US | 20060211692 | A1 | 20060921 | US 2005-551670 | 20050930 |
| US | 20060183739 | A1 | 20060817 | US 2005-551557 | 20051003 <-- |
| US | 20060183742 | A1 | 20060817 | US 2005-551559 | 20051003 |
| IN | 2005KN02182 | A | 20060929 | IN 2005-KN2182 | 20051103 |
| IN | 2005KN02183 | A | 20070323 | IN 2005-KN2183 | 20051103 |
| PRAI DE | 2003-10315377 | A | 20030403 | | |
| DE | 2003-10327428 | A | 20030618 | | |
| DE | 2003-10329295 | A | 20030630 | | |
| DE | 2003-10329457 | A | 20030701 | | |
| US | 2003-483897P | P | 20030702 | | |
| DE | 2003-10334174 | A | 20030726 | | |
| DE | 2003-10336570 | A | 20030808 | | |
| WO | 2004-EP2350 | W | 20040308 | | |
| WO | 2004-EP2405 | W | 20040309 | | |
| WO | 2004-EP2407 | W | 20040309 | | |

OS MARPAT 141:332202
GI




I

AB R1R2(TYX)EWCOGD [R1, R2 = H, O, halo, A, ethynyl, OR3, NO2, cyano, N3, CO2R3, CON(R3)2, NR3COA, NR3SO2A, etc.; R1R2 = toms to form a bicyclic or spirocyclic (heterocyclic) ring; R3 = H, A, etc.; R4 = H, A; W = N, CR3,

C; E = atoms to form a 3-7 membered (double bond containing) (heterocyclic) ring with W; G = [C(R4)2]n, [C(R4)2]nNR3, [C(R4)2]nO, [C(R4)2]nS; X = [C(R4)2]nCONR3[C(R4)2]n, [C(R4)2]nON[C(R4)2]n, etc.; Y = alkylene, cycloalkylene, (substituted) heterocyclylene, arylene; T = mono- or bicyclic substituted (unsatd.) (hetero)cyclyl; A = (fluoro-substituted) alkylene optionally interrupted by O, S, CH:CH; n = 0-2], were prepared Thus, title compound (I) (prepared from 4-(4-aminophenyl)morpholin-3-one, Boc-D-proline, and 4-chlorophenyl isocyanate), bound to Factor Xa receptors with IC50 = 1.8 + 10-8 M.

=> d l11 tot bib abs hitstr

L11 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:273940 CAPLUS <<LOGINID::20080522>>
DN 144:331461
TI Drugs containing carbonyl compounds and their use for the prophylaxis and/or therapy of thromboembolic illnesses
IN Cezanne, Bertram; Dorsch, Dieter; Mederski, Werner; Tsaklakidis, Christos; Gleitz, Johannes
PA Merck Patent G.m.b.H., Germany
SO Ger. Offen., 77 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | DE 102004045796 | A1 | 20060323 | DE 2004-102004045796 | 20040922 |
| | AU 2005287637 | A1 | 20060330 | AU 2005-287637 | 20050824 |
| | CA 2581172 | A1 | 20060330 | CA 2005-2581172 | 20050824 |
| | WO 2006032342 | A2 | 20060330 | WO 2005-EP9124 | 20050824 |
| | WO 2006032342 | A3 | 20070111 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | EP 1791597 | A2 | 20070606 | EP 2005-774750 | 20050824 |
| | R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| | CN 101102818 | A | 20080109 | CN 2005-80031723 | 20050824 |
| | JP 2008513387 | T | 20080501 | JP 2007-531628 | 20050824 |
| | MX 200703175 | A | 20070518 | MX 2007-3175 | 20070316 |
| | KR 2007054210 | A | 20070528 | KR 2007-706440 | 20070321 |
| | US 20080003214 | A1 | 20080103 | US 2007-575711 | 20070321 |
| | IN 2007KN01362 | A | 20070720 | IN 2007-KN1362 | 20070418 |
| PRAI | DE 2004-102004045796 | A | 20040922 | | |
| | WO 2005-EP9124 | W | 20050824 | | |

OS MARPAT 144:331461
GI



I



II

AB Use of heterocyclic carbonyl compds. I [R1, R2 = H, :O,,halogen, A, C.tplbond.CH, OR3,N(R3)2, NO2, CN, N3, CO2R3, CON(R3)2, [C(R4)2]n-Ar, [C(R4)2]n-heterocyclyl, [C(R4)2]n-cycloalkyl, OC(:O)R3, OC(:O)N(R3)2, NR3COA, NR3SO2A; R1R2 = bi- or spirocyclic 3- to 7-membered carbocycle or heterocycle (containing 0 - 3 N, O, or S); R3 = H, A, CH2C.tplbond.CH, CH2CH(OH)CH2OH, CH2CH(OH)CH2NH2, CH2CH(OH)CH2-heterocycle, [C(R4)2]n-Ar, [C(R4)2]n-heterocyclyl, [C(R4)2]n-cycloalkyl, [C(R4)2]n-CO2A, [C(R4)2]nN(R4)2; R4 = H, A; EW = 3- to 7-membered carbocycle or heterocycle (containing 0 - 3 N, O, or S); W = N, CR3, sp2-C; D = mono- or binuclear, (un)substituted aromatic carbocycle or heterocycle (containing 0 - 3 N, O, or S); G = [C(R4)2]n, [C(R4)2]n-NR3, [C(R4)2]nO, [C(R4)2]nS, [CR4:CR4]n; X = [C(R4)2]nCONR3[C(R4)2]n, [C(R4)2]nNR3CO[C(R4)2]n, [C(R4)2]nNR3[C(R4)2]n, [C(R4)2]nO[C(R4)2]n, [C(R4)2]nC(:O)[C(R4)2]n, [C(R4)2]nCO2[C(R4)2]n; Y = alkylene, cycloalkylene, heterodiyl, aryldiyl; T = mono- or binuclear, (un)substituted aromatic carbocycle or heterocycle (containing 0 - 3 N, O, or S); A = (un)branched C1-10-alkyl (optionally containing, O, S or CH:CH in the chain and replacing 1 - 7 H with F); n = 0 - 2; o = 1 - 3], their derivs., solvates, salts and stereoisomers, for the prophylaxis and/or therapy of thromboembolic illnesses. Thus, proline derivative II was prepared from N-Boc-D-proline via amidation with 4-(4-aminophenyl)morpholin-3-one in DMF containing 1-hydroxybenzotriazole hydrate, N-[3-(dimethylamino)propyl]-N'-ethylcarbodiimide hydrochloride and N-methylmorpholine, N-deprotection with aqueous HClin dioxane and carbamylation with 4-ClC6H4NCO in CH2Cl2 containing Et3N. The receptor binding activity of II was determined [IC50 = 1.8 x 10-8 M vs. FXa; IC50 = 2.3 x 10-8 M vs. TF/FVIIa].

IT 773888-69-0P 774602-56-1P 774602-57-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drugs containing carbonyl compds. and their use for the prophylaxis and/or therapy of thromboembolic illnesses)

RN 773888-69-0 CAPLUS

CN 1,2-Piperidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 774602-56-1 CAPLUS
CN 1,3-Piperidinedicarboxamide, N1-(4-chlorophenyl)-N3-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 774602-57-2 CAPLUS
CN 1,3-Piperidinedicarboxamide, N1-(4-chlorophenyl)-N3-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)



L11 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:143100 CAPLUS <<LOGINID::20080522>>
DN 140:199315
TI Preparation of iminothiazolidinone amino acid derivatives as inhibitors of

HCV replication

IN Romine, Jeffrey Lee; Martin, Scott W.; Snyder, Lawrence B.; Serrano-Wu, Michael; Deshpande, Milind; Whitehouse, Darren; Lemm, Julie; O'Boyle, Donald; Gao, Min; Colonno, Richard

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 127 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2004014852 | A2 | 20040219 | WO 2003-US24717 | 20030808 |
| | WO 2004014852 | A3 | 20040422 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | AU 2003261434 | A1 | 20040225 | AU 2003-261434 | 20030808 |
| | US 20050069522 | A1 | 20050331 | US 2003-637156 | 20030808 |
| | US 20050096364 | A1 | 20050505 | US 2003-637099 | 20030808 |
| | US 7183302 | B2 | 20070227 | | |
| PRAI | US 2002-402661P | P | 20020812 | | |
| | US 2002-403694P | P | 20020815 | | |
| | WO 2003-US24717 | W | 20030808 | | |

OS MARPAT 140:199315

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compound I [R1 = C1-C6 alkyl, C3-C7 cycloalkyl, C6-C10 aryl, C1-C6 alkoxy, C6-C10 aryloxy, C6-C10 aryl(C1-C6)alkyl, C6-C10 aryl(C1-C6)alkoxy, etc.; R2, R3 = independently C1-C6 alkyl, C3-C7 cycloalkyl, C6-C10 aryl, C1-C6 alkoxy, C6-C10 aryloxy, heterocyclyl, C6-C10 aryl(C1-C6)alkyl, C6-C10 aryl(C1-C6)alkoxy, etc., with the proviso that one of R2 or R3 can be a bond and R2 and R3 are joined to form a cyclic structure; R4 = C1-C4 alkyl, optionally substituted with 1-3 halo, 1-3 oxygen, or 1-3 nitrogen, said R4 having an S stereoconfiguration; R5 = H or a bond wherein R4 and R5 are joined to form a cyclic structure] were prepared as inhibitors of HCV replication. Thus, reaction of 5-(4-aminophenyl)-2-(3-fluorophenylimino)-3-furan-2-ylmethylthiazolidin-4-one (preparation given) with N-benzyloxycarbonyl-L-alanyl chloride gave compound II. The prepared compds. were assayed for the inhibition of HCV replicon cell line and were classified with activity of EC50 < 0,1 μM, 0.1 μM ≤ EC50 ≤ 1 μM, 1 μM ≤ EC50 ≤ 5 μM, or EC50 ≥ 5 μM.

IT 657414-07-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of iminothiazolidinone amino acid derivs. as inhibitors of HCV replication)

RN 657414-07-8 CAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]-N1-(phenylmethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L11 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:142910 CAPLUS <<LOGINID::20080522>>
DN 140:199742
TI Preparation of iminothiazolidinone amino acid derivatives as combination pharmaceutical agents for use as inhibitors of HCV replication
IN Colonno, Richard; Lemm, Julie; O'Boyle, Donald; Gao, Min; Romine, Jeffrey Lee; Martin, Scott W.; Snyder, Lawrence B.; Serrano-Wu, Michael; Deshpande, Milind; Whitehouse, Darren
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2004014313 | A2 | 20040219 | WO 2003-US25036 | 20030808 |
| | WO 2004014313 | A3 | 20051215 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2003264038 | A1 | 20040225 | AU 2003-264038 | 20030808 |
| | US 20050069522 | A1 | 20050331 | US 2003-637156 | 20030808 |
| | US 20050096364 | A1 | 20050505 | US 2003-637099 | 20030808 |
| | US 7183302 | B2 | 20070227 | | |
| PRAI | US 2002-402661P | P | 20020812 | | |
| | US 2002-403694P | P | 20020815 | | |

WO 2003-US25036 W 20030808
OS MARPAT 140:199742
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed are combination pharmaceutical agents for the treatment of an HCV infection comprising a compound which is effective in inhibiting the function of the HCV NS5A protein and another compound having anti-HCV activity. Compds. which can inhibit the function of the NS5A protein have structure I [R1, R2, R3 are (cyclo)alkyl, aryl, alkoxy, aryloxy, arylalkyl, etc.; R4 is alkyl, optionally substituted by halogen, oxygen, or nitrogen; R2/R3 and R4/R5 can form rings] or their pharmaceutically-acceptable salt or prodrugs. Compds. having anti-HCV activity are selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, etc. Thus, compound II was prepared by reaction of 5-(4-aminophenyl)-2-[(3-fluorophenyl)imino]-3-(furan-2-ylmethyl)thiazolidin-4-one (preparation given) with N-(benzyloxycarbonyl)-L-alanyl chloride (Cbz-L-Ala-Cl) and showed EC50 = 0.1-1 μM in the HCV replicon cell line assay.

IT 657414-07-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of iminothiazolidinone amino acid derivs. as combination pharmaceutical agents for use as inhibitors of HCV replication)

RN 657414-07-8 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]-N1-(phenylmethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.